Characteristics of Patients Treated With HRS-3/A9
| Patient No. . | Gender . | Age (yr) . | Histology* . | Involved Sites . | Relapse No. . | Previous Therapy . |
|---|---|---|---|---|---|---|
| 1 | Male | 37 | Nod-scl | OSS | 2 | 3× COPP/ABVD, radiotherapy, 2× Vbl |
| 2 | Male | 37 | Nod-scl | OSS, LN | 2 | 6× COPP, radiotherapy, 6× ABVD |
| 3 | Male | 44 | Nod-scl | PUL, HEP, SPL, LN | 6 | 6× COPP, 5× COPP/ABVD, 1× Mtx/VP-16/Ifo, radiotherapy, 4× Vbl/Adr/Dex, 3× DexaBEAM, 1× ADR/CDDP/Ara-C |
| 4 | Female | 44 | Mixed | BM, LN | 4 | 5× COPP, radiotherapy, 2× COPP/ABVD/IEV, radiotherapy, 5× IEV, 3× PVB |
| 5 | Male | 42 | Mixed | PUL, OSS, LN | 2 | 4× COPP/ABVD, radiotherapy, 1× DexaBEAM |
| 6 | Female | 57 | Mixed | BM, LN | 2 | 4× COPP/ABV/IMEP, radiotherapy, 7× CEP |
| 7 | Female | 36 | Nod-scl | PUL, LN | 3 | 2× COPP/ABVD, radiotherapy, 2× DexaBEAM, PBSCT (BEAM), 4× Ifo/VP-16, 6× VBL/Pred |
| 8 | Male | 45 | Mixed (NA) | PUL | 4 | 6× ABVD, radiotherapy, 4× ABVD, 6× MOPP, 6× CEVD, 2× DexaBEAM, PBSCT (CVB), interleukin-4 |
| 9 | Female | 29 | Nod-scl | OSS, Soft tissue | 4 | Radiotherapy, 3× COPP/ABVD, radiotherapy, 2× DexaBEAM, ABMT (CVB) |
| 10 | Male | 25 | Unclassifiable (NA) | OSS, SPL, LN | 2 | 4× COPP/ABVD, VIP-E, PBSCT (BEAM), 7× Taxol, 6× Vbl/Pred |
| 11 | Female | 54 | Unclassifiable (NA) | PUL | 4 | 4× COPP, radiotherapy, CEVD, 2× ACOP-E, IMEP, ABMT (EBAC), 4× Vbl, 4× CEP, Taxol, VACOP-B, 2× Dex/Procarbacin |
| 12 | Male | 26 | Nod-scl (NA) | PUL, HEP, BM, LN | 4 | 3× COPP/ABVD, 4× DexaBEAM, radiotherapy, 10× Pm, 2× A-SHAP |
| 13 | Female | 26 | Nod-scl (NA) | PUL, LN | 2 | 1× COPP/ABVD, 3× DexaBEAM, ABMT (Cy/VP-16), 2× CCNU/Pred, 2× CDDP, 5× IEV, 4× COPP |
| 14 | Female | 58 | Mixed (NA) | PUL, HEP | 3 | Radiotherapy, 3× MOPP/ABVD, 2× MOPP/ABVD, 2× MINE, ABMT (BEAM), 2× Vbl, MEVAC |
| 15 | Male | 41 | Nod-scl | OSS, LN | 1 | COPP, DexaBEAM, 6× CEP |
| Patient No. . | Gender . | Age (yr) . | Histology* . | Involved Sites . | Relapse No. . | Previous Therapy . |
|---|---|---|---|---|---|---|
| 1 | Male | 37 | Nod-scl | OSS | 2 | 3× COPP/ABVD, radiotherapy, 2× Vbl |
| 2 | Male | 37 | Nod-scl | OSS, LN | 2 | 6× COPP, radiotherapy, 6× ABVD |
| 3 | Male | 44 | Nod-scl | PUL, HEP, SPL, LN | 6 | 6× COPP, 5× COPP/ABVD, 1× Mtx/VP-16/Ifo, radiotherapy, 4× Vbl/Adr/Dex, 3× DexaBEAM, 1× ADR/CDDP/Ara-C |
| 4 | Female | 44 | Mixed | BM, LN | 4 | 5× COPP, radiotherapy, 2× COPP/ABVD/IEV, radiotherapy, 5× IEV, 3× PVB |
| 5 | Male | 42 | Mixed | PUL, OSS, LN | 2 | 4× COPP/ABVD, radiotherapy, 1× DexaBEAM |
| 6 | Female | 57 | Mixed | BM, LN | 2 | 4× COPP/ABV/IMEP, radiotherapy, 7× CEP |
| 7 | Female | 36 | Nod-scl | PUL, LN | 3 | 2× COPP/ABVD, radiotherapy, 2× DexaBEAM, PBSCT (BEAM), 4× Ifo/VP-16, 6× VBL/Pred |
| 8 | Male | 45 | Mixed (NA) | PUL | 4 | 6× ABVD, radiotherapy, 4× ABVD, 6× MOPP, 6× CEVD, 2× DexaBEAM, PBSCT (CVB), interleukin-4 |
| 9 | Female | 29 | Nod-scl | OSS, Soft tissue | 4 | Radiotherapy, 3× COPP/ABVD, radiotherapy, 2× DexaBEAM, ABMT (CVB) |
| 10 | Male | 25 | Unclassifiable (NA) | OSS, SPL, LN | 2 | 4× COPP/ABVD, VIP-E, PBSCT (BEAM), 7× Taxol, 6× Vbl/Pred |
| 11 | Female | 54 | Unclassifiable (NA) | PUL | 4 | 4× COPP, radiotherapy, CEVD, 2× ACOP-E, IMEP, ABMT (EBAC), 4× Vbl, 4× CEP, Taxol, VACOP-B, 2× Dex/Procarbacin |
| 12 | Male | 26 | Nod-scl (NA) | PUL, HEP, BM, LN | 4 | 3× COPP/ABVD, 4× DexaBEAM, radiotherapy, 10× Pm, 2× A-SHAP |
| 13 | Female | 26 | Nod-scl (NA) | PUL, LN | 2 | 1× COPP/ABVD, 3× DexaBEAM, ABMT (Cy/VP-16), 2× CCNU/Pred, 2× CDDP, 5× IEV, 4× COPP |
| 14 | Female | 58 | Mixed (NA) | PUL, HEP | 3 | Radiotherapy, 3× MOPP/ABVD, 2× MOPP/ABVD, 2× MINE, ABMT (BEAM), 2× Vbl, MEVAC |
| 15 | Male | 41 | Nod-scl | OSS, LN | 1 | COPP, DexaBEAM, 6× CEP |
Abbreviations: NA, histology at presentation because no rebiopsy taken immediately before BiMab treatment was available; Nod-scl, nodular sclerosis; mixed, mixed cellularity; OSS, bone; LN, lymph nodes; PUL, lung; HEP, liver; SPL, spleen; BM, bone marrow; ABMT, Autologous bone marrow transplantation; PBSCT, PB stem cell transplantation; ACOP-E, adriamycin, cyclophosphamide, vincristine, prednisone, etoposide; ABVD, adriamycin, bleomycin, vinblastin, dacarbacine; A-SHAP, adriamycin, prednisolone, cytosine-arabinoside, cisplatin; BEAM, BCNU, etoposide, cytosine-arabinoside, melphalan; CEP, CCNU, etoposide, prednimustine; CEVD, CCNU, etoposide, vinblastine, dexamethasone; CVB, cyclophosphamide, etoposide, BCNU; COPP, cyclophosphamide, vincristine, procarbazine, prednisone; DexaBEAM, dexamethasone, BCNU, etoposide, cytosine-arabinoside, melphalan; EBAC; etoposide, BCNU, cytosine-arabinoside, cyclophosphamide; IEV, ifosfamide, etoposide, vinblastin; IMEP, ifosfamide, methotrexate, etoposide, prednisone; MEVAC, mitoguazone, etoposide, vindesine, adriamycin, prednisone; MINE, mitoguazone, ifosfamide, vinorelbine, etoposide; MOPP, nitrogen mustard, vincristine, procarbazine, prednisone; PVB, cisplatin, vinblastin, bleomycin; VACOP-B, etoposide, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin; VIP-E, etoposide, ifosfamide, carboplatin, epirubicin; ADR, doxorubicin; Ara-C, cytosine-arabinoside; CDDP, cisplatin; Cy, cyclophosphamide; Dex, dexamethasone; Ifo, ifosfamide; MTX, methotrexate; Pm, prednimustine; Pred, prednisone; VBL, vinblastine; VP-16, etoposide.
Only CD30+ histologies were treated.